

In the specification:

Please replace the first complete paragraph on page 27 with the following:

CAB domains of this invention are composite ligand binding domains, comprising a portion of calcineurin A and a portion of calcineurin B, such that the resulting composite ligand binding domain contains the surface of calcineurin phosphatase that contacts the FKBP-FK506 complex. The region of calcineurin that has been truncated contains the autoregulatory and calmodulin domains, which are not involved in FKBP binding. By way of example, the nucleic acid and amino acid sequences of human calcineurin A are provided in SEQ ID NO: 32 and SEQ ID NO: 33, respectively, and the nucleic acid and amino acid sequences of human calcineurin B are provided in SEQ ID NO: 34 and SEQ ID NO: 35, respectively. The portion of calcineurin A used in the examples includes residues 12 to 394 or residues 12 to 370 of human calcineurin A in the full length CABS, however, equivalent regions of the calcineurin gene from other species could also be used. For example, one may desire to use the sequence of the mouse or rat genes for the construction of transgenic animals. The N or C terminus of the calcineurin A portion could also be shortened or extended, if desired. The 12-394 CABSs contain an active phosphatase domain, while the 12-370 CABs have an H151A mutation in calcineurin A that abolishes the phosphatase activity.